<DOC>
	<DOCNO>NCT03095482</DOCNO>
	<brief_summary>This double-blind randomized control clinical trial aim test whether transcranial direct current stimulation ( tDCS ) use modulate fear extinction learning exposure therapy pathological fear , include fear spider , snake , tightly enclose space , germ / contamination . Participation take place three laboratory visit , include ( 1 ) pre-treatment visit , ( 2 ) treatment post-treatment visit , ( 3 ) 1 month follow-up visit . During treatment , participant receive either 20 minute active sham tDCS , follow 30 minute vivo exposure therapy .</brief_summary>
	<brief_title>tDCS-Augmented Exposure Therapy Pathological Fear</brief_title>
	<detailed_description>In trans-diagnostic sample mark pathological fear behavioral avoidance , study aim : ( 1 ) evaluate whether excitatory tDCS mPFC inhibitory tDCS right dlPFC enhances exposure therapy relative ( ) tDCS use electrode positioning , reverse polarity , ( b ) sham tDCS ; ( 2 ) determine whether reversed polarity tDCS impede extinction learning ; ( 3 ) determine whether tDCS effect mediate pre-post change vigilance threat , in-session fear reduction , contextual memory exposure context . If successful , project may discover potentially effective exposure therapy augmentation , may enhance knowledge behavioral , cognitive , affective , neurobiological factor moderate mediate acute treatment response maintenance treatment gain . This knowledge may inform treatment development effort debilitate form pathological fear .</detailed_description>
	<criteria>1 . Age 1865 . 2 . Fluent English . 3 . A score least 1 fear domainspecific prescreen measure &gt; 2 SDs subject pool prescreen mean . These measure include ( ) CLQ , ( b ) FSQ , ( c ) OCIR . 4 . Peak fear â‰¥ 50 BATs 1 2 . 1 . Currently receive treatment primary fear domain ( base clinical interview ) . 2 . Unstable dose psychotropic medication within 6 week prior baseline assessment ( base DMQ ; see measure ) . 3 . Medical condition would contraindicate participation treatment assessment activity ( e.g. , cardiovascular problem ; base DMQ ; see measure ) . 4 . Pregnancy ( base DMQ ; see measure ) . 5 . Current major depressive disorder ( base MINI ; see measure ) . 6 . Current , history bipolar disorder ( base MINI ; see measure ) . 7 . Current , history psychotic symptom ( base MINI ; see measure ) . 8 . Serious suicidal risk , determine selfreport ( CSSRS , BDIII ) clinical interview ( MINI ; see measure ) . 9 . Active neurological condition , include seizure , stroke , unexplained loss consciousness concussion ( base DMQ tDCS Safety Screening Form ; see measure ) 10 . Contraindications tDCS : Metal head implant brain medical device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Arachnophobia ( fear spider )</keyword>
	<keyword>Ophidophobia ( fear snake )</keyword>
	<keyword>Claustrophobia ( fear tightly enclose space )</keyword>
	<keyword>Germaphobia ( fear germ , dirtiness , contamination )</keyword>
</DOC>